MEDICATION ADHERENCE COMPARING TOBRAMYCIN INHALATION POWDER AND SOLUTION IN PATIENTS WITH CYSTIC FIBROSIS USING THE DUTCH PHARMO DATABASE NETWORK

被引：0
|
作者：
Overbeek, J. [2 ]
Kuiper, J. [2 ]
Evers, K. [3 ]
Putzeist, M. [3 ]
Mastoridis, P. [1 ]
Ong, S. H. [4 ]
Herk-Sukel, M. [2 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] PHARMO Inst, Utrecht, Netherlands
[3] Novartis Pharma BV, Arnhem, Netherlands
[4] Novartis Pharma AG, Basel, Switzerland
来源：
PEDIATRIC PULMONOLOGY | 2015年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
460
引用
收藏
页码：365 / 365
页数：1
相关论文
共 50 条
  • [21] Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
    Hamed, Kamal
    Conti, Valentino
    Tian, Hengfeng
    Loefroth, Emil
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 831 - 838
  • [22] Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis
    LeLorier, J
    Perreault, S
    Birnbaum, H
    Greenberg, P
    Sheehy, O
    CLINICAL THERAPEUTICS, 2000, 22 (01) : 140 - 151
  • [23] Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection
    Waters, Valerie
    Yau, Yvonne
    Beaudoin, Trevor
    Wettlaufer, Jillian
    Tom, Sean Kevin
    McDonald, Nancy
    Rizvi, Leena
    Klingel, Michelle
    Ratjen, Felix
    Tullis, Elizabeth
    JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (04) : 492 - 495
  • [24] A REAL WORLD ASSESSMENT OF PATIENT EXPERIENCE WITH TOBRAMYCIN INHALATION POWDER (TIP) AMONG PATIENTS WITH CYSTIC FIBROSIS
    Greenberg, J.
    Palmer, J.
    Chan, W.
    Correia, C.
    Whalley, D.
    Shannon, P.
    Sawicki, G. S.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 377 - 377
  • [25] PILOT TRIAL OF TOBRAMYCIN INHALATION POWDER IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC BURKHOLDERIA CEPACIA COMPLEX INFECTION
    Waters, V. J.
    Yau, Y.
    Ratjen, F.
    Tullis, E.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 319 - 319
  • [26] IMPACT OF INITIATION OF TOBRAMYCIN SOLUTION FOR INHALATION (TIS) ON QUALITY OF LIFE AMONG PATIENTS WITH CYSTIC FIBROSIS (CF)
    Wertz, D. A.
    Stephenson, J. J.
    Hsieh, H.
    Chang, C.
    Zhang, J.
    Kuhn, R. J.
    PEDIATRIC PULMONOLOGY, 2011, : 341 - 341
  • [27] Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Srilekha Panguluri
    Praveen Gunda
    Laurie Debonnett
    Kamal Hamed
    Clinical Drug Investigation, 2017, 37 : 795 - 805
  • [28] Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Kate McKeage
    Drugs, 2013, 73 : 1815 - 1827
  • [29] Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
    Panguluri, Srilekha
    Gunda, Praveen
    Debonnett, Laurie
    Hamed, Kamal
    CLINICAL DRUG INVESTIGATION, 2017, 37 (08) : 795 - 805
  • [30] Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system
    Geller, DE
    Rosenfeld, M
    Waltz, DA
    Wilmott, RW
    CHEST, 2003, 123 (01) : 28 - 36
12345